Clinical trials: Severe Respiratory Distress
SARS-CoV Infection
VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).
- Trial name
- VERU-111 (NCT04842747)
- Testing
- VERU-111
- Where
- 58 sites in United States, Argentina and 4 more
- Volunteers
- 204 people
- Sponsor
- Veru Inc.
SARS-CoV2 Infection, COVID-19 Acute Respiratory Distress Syndrome
Impact of COVID-19 SARS-CoV-2 Variability in ICU Hospitalized Patients With Severe Disease
Background:The impact of the emergence of SARS-CoV-2 variants on the severity and clinical outcomes of COVID-19 is controversial.
- Conditions
- SARS-CoV2 Infection, COVID-19 Acute Respiratory Distress Syndrome, Mutation
- Trial name
- SEVARVIR (NCT05162508)
- Testing
- Nasopharyngeal swab
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Extracorporeal Membrane Oxygenation Complication, ARDS (Acute Respiratory Distress Syndrome)
RECOMMEND Platform Trial
The goal of this platform trial is to determine the efficacy, safety and cost-effectiveness of various interventions in patients with acute cardiorespiratory failure requiring extracorporeal membrane oxygenation (ECMO) The main…
- Conditions
- Extracorporeal Membrane Oxygenation Complication, ARDS (Acute Respiratory Distress Syndrome), Intensive Care Medicine, Cardiac Arrest (CA)
- Trial name
- RECOMMEND (NCT06526533)
- Testing
- Liberal RBC Transfusion, Restrictive RBC Transfusion
- Where
- 3 sites in Australia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
Severe to Critical COVID 19 With Associated ARDS
A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19
This is a Phase 2/3, randomized, double blind, placebo controlled, multicenter study to evaluate the efficacy and safety of FP-025 in adult patients with severe to critical COVID 19 with associated ARDS.
- Trial name
- NCT04750278
- Testing
- FP-025 100 mg, FP-025 300 mg
- Where
- 8 sites in United States
- Volunteers
- 90 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
The purpose of this clinical trial is to determine the best initial non-invasive respiratory support (NIRS) strategy for adults who present to the emergency department with acute hypoxemic respiratory failure, a condition in…
- Trial name
- WINDSURFER (NCT07558265)
- Testing
- Non-Invasive Positive Pressure Ventilation, High Flow Nasal Oxygen
- Where
- 6 sites in United States
- Volunteers
- 500 people
- Sponsor
- Ohio State University
Acute Respiratory Distress Syndrome (ARDS)
Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS
A Phase 2a, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of ALT-100mAb in patients with moderate to severe ARDS.
- Trial name
- NCT05938036
- Testing
- ALT-100 mAb
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Aqualung Therapeutics Corp.
Respiratory Distress Syndrome, Adult
Ultra-protective Pulmonary Ventilation Supported by Low Flow ECCO2R for Severe ARDS
This study evaluates the use of ultra-protective ventilation, where very low ventilation volumes are used, in patients with severe acute respiratory distress syndrome (ARDS) meeting criteria to nurse in the prone position.
- Trial name
- U-Protect (NCT02252094)
- Testing
- Prismalung, Ultra-protective ventilation, Conventional Lung Protective Ventilation
- Where
- 2 sites in Singapore
- Volunteers
- 8 people
- Sponsor
- National University Health System, Singapore
Severe Acute Respiratory Syndrome Coronavirus 2, Severe Acute Respiratory Distress Syndrome
Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS
Whereas the pandemic due do Covid-19 continues to spread, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes Severe Acute Respiratory Distress Syndrome in 30% of patients with a 30%-60% mortality rate for…
- Trial name
- STROMA-CoV2 (NCT04333368)
- Testing
- Umbilical cord Wharton's jelly-derived human, NaCl 0.9%
- Where
- 2 sites in France
- Volunteers
- 47 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Respiratory Distress Syndrome (ARDS)
Study of Xuanbai Shengmai Decoction in the Treatment of Acute Respiratory Distress Syndrome
Acute respiratory distress syndrome (ARDS) is a common clinical syndrome in the ICU characterized by extremely high mortality and complex pathogenesis.At present, research on individualized treatment, phenotypic differences, and…
- Trial name
- NCT07528196
- Testing
- Xuanbai Shengmai Decoction
- Volunteers
- 308 people
- Sponsor
- Southeast University, China
Viral Lung Infection and Acute Respiratory Failure
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
- Trial name
- TILIA (NCT05624450)
- Testing
- Tozorakimab
- Where
- 473 sites in United States, Argentina and 37 more
- Volunteers
- 3,527 people
- Sponsor
- AstraZeneca
Covid19, SARS-CoV Infection
Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome
Acute treatment of COVID-ARDS with direct topical lung instilled T3 therapy for patients on mechanical ventilation.
- Conditions
- Covid19, SARS-CoV Infection, ARDS, ARDS, Human
- Trial name
- NCT04725110
- Testing
- Instilled T3
- Where
- United States
- Sponsor
- University of Minnesota
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe)
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)
This is a multi-center, randomized, placebo controlled, interventional phase 2A trial to evaluate the safety profile and potential efficacy of multi-dosing of mesenchymal stromal cells (MSC) for patients with SARS-CoV-2…
- Conditions
- Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
- Trial name
- NCT04466098
- Testing
- Mesenchymal stromal cells
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Covid19
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
This study looks at the safety and effectiveness of Remdesivir in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure.
- Trial name
- NCT06729593
- Testing
- Remdesivir, Corticosteroid
- Where
- 40 sites in United States
- Volunteers
- 87 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Insufficiency
High Flow Nasal Oxygen at Extubation for Adults Requiring a Breathing Tube for Treating Severe Breathing Difficulties
The goal of this feasibility study is to learn whether a new approach to breathing tube removal within the Intensive Care Unit is safe and acceptable to participants who require a breathing tube for the management of severe…
- Trial name
- Pre-SAFEx (NCT05904652)
- Testing
- Fisher and Paykel "HealthCare Airvo™ 3" high flow system, Conventional Oxygen Therapy
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- NHS Greater Glasgow and Clyde
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Tocilizumab for Patients With Cancer and COVID-19 Disease
This phase II expanded access trial will study how well tocilizumab works in reducing the serious symptoms including pneumonitis (severe acute respiratory distress) in patients with cancer and COVID-19.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis
- Trial name
- NCT04370834
- Testing
- Tocilizumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
ARDS, Lung Protective Ventilation
Effect of Different Depths of Neuromuscular Blockade on Respiratory Mechanics in Patients With Moderate-severe Acute Respiratory Distress Syndrome
Acute respiratory distress syndrome (ARDS) is characterized by acute diffuse alveolar injury caused by a variety of pulmonary and extrapulmonary factors, leading to refractory hypoxemia. It has high incidence and mortality rates.
- Trial name
- ARDS (NCT06514209)
- Testing
- cisatracurium
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Southeast University, China
Severe Pneumonia, Acute Respiratory Distress Syndrome
Treatment of COVID-19 Positive/Negative Bangladeshi Adults With Severe Respiratory Complaints by a Locally Made bCPAP: Feasibility Study
Low and middle-income countries (LMICs) urgently need cost-effective adaptive technologies to provide CPAP. The lead investigator has designed a device that has already been approved by the Directorate General of Drug…
- Conditions
- Severe Pneumonia, Acute Respiratory Distress Syndrome, Covid19
- Trial name
- Adult-bCPAP (NCT05158842)
- Testing
- Adult bubble CPAP oxygen therapy device
- Where
- 2 sites in Bangladesh
- Volunteers
- 20 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
COVID, Severe Acute Respiratory Syndrome
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
To evaluate the proportion of subjects alive and free of respiratory failure (e.g. need for non-invasive or invasive mechanical ventilation, high flow oxygen, or ECMO) and free of the need for continued renal replacement therapy…
- Conditions
- COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury
- Trial name
- NCT04402957
- Testing
- LSALT peptide
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 61 people
- Sponsor
- Arch Biopartners Inc.
Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS)
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia
This is a Phase 3, randomized, blinded, and placebo-controlled clinical trial investigating a new combination treatment for critically ill adults who have severe community-acquired pneumonia, especially if they also have sepsis…
- Conditions
- Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis, Lymphopenia
- Trial name
- NCT07492875
- Testing
- Nogapendekin alfa inbakicept (NAI), agenT-797
- Sponsor
- ImmunityBio, Inc.
Acute Respiratory Distress Syndrome, Infections
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS…
- Trial name
- NCT05947955
- Testing
- Rhu-pGSN, normal saline
- Where
- 65 sites in United States, Belgium and 11 more
- Volunteers
- 600 people
- Sponsor
- BioAegis Therapeutics Inc.